Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1 / Phase 2NCT05379985
Official study title

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Study summary

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRMC-6236

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 15, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?21 U.S. locations

Locations may change over time.

Who runs it?Revolution Medicines, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Revolution Medicines, Inc.
Interventions being studied
Drug: RMC-6236
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
  • Treatment naive or have received prior standard therapy appropriate for tumor type and stage
  • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Primary central nervous system (CNS) tumors
  • Active, untreated brain metastases
  • Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
  • History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy Other inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • UC Irvine/Chao Family Comprehensive Cancer CenterOrange, California
  • UCLASanta Monica, California
  • Moffitt Cancer CenterTampa, Florida
  • Piedmont HealthcareAtlanta, Georgia
  • Mary Bird Perkins Cancer CenterBaton Rouge, Louisiana
  • Johns Hopkins UniversityBaltimore, Maryland
  • Dana Farber Cancer InstituteBoston, Massachusetts
  • Perlmutter Cancer Center at NYU Langone HealthNew York, New York
  • Memorial Sloan-Kettering Cancer CenterNew York, New York
  • Columbia UniversityNew York, New York
  • Christ Hospital Cancer CenterCincinnati, Ohio
  • Taylor Cancer Research CenterMaumee, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2026. Always confirm current availability with the study team.

View original record ↗